Beijing-based METiS TechBio is leading advancements in longevity science by utilizing AI to address the errors in human DNA that contribute to aging. CEO Lai Tsai-ta compares aging to software bugs, noting that reprogramming immune cells like T cells could enhance their function and reduce disease susceptibility in older individuals. The company recently raised $269.5 million in an IPO, attracting major investors like BlackRock and UBS. While cellular reprogramming is still in its early stages, the U.S. remains the dominant force in this sector, representing a significant portion of global investments in longevity research, which totaled $8.49 billion.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://amp.scmp.com/business/china-business/article/3356154/targeting-us610-billion-longevity-market-biotech-firms-race-reverse-ageing
